Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Diabetes 55:3271-3278, 2006
DOI: 10.2337/db06-0627
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cozar-Castellano, I.
Right arrow Articles by Stewart, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cozar-Castellano, I.
Right arrow Articles by Stewart, A. F.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Cell Cycle Inhibitory Protein p21cip Is Not Essential for Maintaining ß-Cell Cycle Arrest or ß-Cell Function In Vivo

Irene Cozar-Castellano, Marcia Haught, and Andrew F. Stewart

From the Division of Endocrinology, The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Address correspondence and reprint requests to Irene Cozar-Castellano, PhD, Division of Endocrinology, BST E-1140, University of Pittsburgh School of Medicine, 200 Lothrop St., Pittsburgh, PA 15213. E-mail: cozari{at}dom.pitt.edu

Abbreviations: BrdU, bromodeoxyuridine; HGF, hepatocyte growth factor; MEF, mouse embryonic fibroblast; PKB, protein kinase B; PL, placental lactogen; PRL, prolactin; RIP, rat insulin II promoter

p21cip1, a regulatory molecule upstream of the G1/0 checkpoint, is increased in ß-cells in response to mitogenic stimulation. Whereas p21cip1 can variably stimulate or inhibit cell cycle progression, in vitro studies suggest that p21cip1 acts as an inhibitor in the pancreatic ß-cell. To determine the functional role of p21cip1 in vivo, we studied p21-null mice. Surprisingly, islet mass, ß-cell replication rates, and function were normal in p21-null mice. We next attempted to drive ß-cell replication in p21-null mice by crossing them with rat insulin II promoter–murine PL-1 (islet-targeted placental lactogen transgenic) mice. Even with this added replicative stimulus of PL, p21-null islets showed no additional stimulation. A G1/S proteome scan demonstrated that p21cip1 loss was not associated with compensatory increases in other cell cycle inhibitors (pRb, p107, p130, p16, p19, and p27), although mild increases in p57 were apparent. Surprisingly, p18, which had been anticipated to increase, was markedly decreased. In summary, isolated p21cip1 loss, as for pRb, p53, p18, and p27 and other inhibitors, results in normal ß-cell development and function, either because it is not essential or because its function is subserved or complimented by another protein. These studies underscore marked inhibitory pressure and the complexity and plasticity of inhibitory pathways that restrain ß-cell replication.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.